¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Arrenius activation energy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • energy flux density
    ¿¡³ÊÁö¿òÁ÷Àӹеµ, ¿¡³ÊÁöÀ¯µ¿¹Ðµµ
  • energy metabolic rate
    ¿¡³ÊÁö´ë»çÀ²
  • energy quantum
    ¿¡³ÊÁö¾çÀÚ
  • energy transfer coefficient
    ¿¡³ÊÁöÀüÀ̰è¼ö
  • energy-rich bond
    °í¿¡³ÊÁö°áÇÕ
  • free energy
    ÀÚÀ¯¿¡³ÊÁö
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ
  • high energy compound
    °í¿¡³ÊÁöÈ­ÇÕ¹°
  • high energy phosphate compound
    °í¿¡³ÊÁöÀλ꿰ȭÇÕ¹°
  • kinetic energy
    ¿îµ¿¿¡³ÊÁö
  • mass energy absorption coefficient
    Áú·®¿¡³ÊÁöÈí¼ö°è¼ö
  • mass energy transfer coefficient
    Áú·®¿¡³ÊÁöÀüÀ̰è¼ö
  • nuclear energy
    ÇÙ¿¡³ÊÁö
  • potential energy
    ÀüÀ§¿¡³ÊÁö, À§Ä¡¿¡³ÊÁö
  • radiant energy
    ¹æ»ç¿¡³ÊÁö, º¹»ç¿¡³ÊÁö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • energy-rich bond
    (¢¡high energy bond) °í¿¡³ÊÁö°áÇÕ
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ
  • energy absorption coefficient
    ¿¡³ÊÁöÈí¼ö°è¼ö
  • energy transfer coefficient
    ¿¡³ÊÁöÀüÀ̰è¼ö
  • mass energy absorption coefficient
    Áú·®¿¡³ÊÁöÈí¼ö°è¼ö
  • mass energy transfer coefficient
    Áú·®¿¡³ÊÁöÀüÀ̰è¼ö
  • energy flux density
    ¿¡³ÊÁö¼Ó¹Ðµµ
  • total potential energy difference
    ÃÑÀ§Ä¡¿¡³ÊÁöÂ÷
  • energy
    ¿¡³ÊÁö
  • electronic energy level
    ÀüÀÚ¿¡³ÊÁö¼öÁØ
  • energy quantum
    ¿¡³ÊÁö¾çÀÚ
  • energy spectrum
    ¿¡³ÊÁö½ºÆåÆ®·³
  • energy fluence rate
    ¿¡³ÊÁöÇ÷ç¾ð½ºÀ², ¿¡³ÊÁö¿µÇâ·ü
  • energy metabolic rate
    ¿¡³ÊÁö´ë»çÀ²
  • free energy
    ÀÚÀ¯¿¡³ÊÁö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • High energy phosphate
    °í¿¡³ÊÁöÀλê
  • absorption energy
    Èí¼ö¿¡³ÊÁö
  • acoustic energy
    À½Çâ¿¡³ÊÁö
  • free energy
    ÀÚÀ¯(í»ë¦)¿¡³ÊÁö.
  • high energy bond
    °í¿¡³ÊÁö °áÇÕ
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ.
  • high energy phosphate bond
    °í¿¡³ÊÁöÀλ꿰°áÇÕ.
  • high energy radiation
    °í¿¡³ÊÁö¹æ»ç¼±
  • high linear energy transfer radiation
    °í¼±Çü¿¡³ÊÁöÀüÀ̹æ»ç¼±
  • pressure energy
    ¾Ð·Â (äâÕô) ¿¡³ÊÁö
  • protein-energy malnutrition
    ´Ü¹é(Áú)¿¡³ÊÁö¿µ¾ç½ÇÁ¶(Áõ)(¡­ç½å×ã÷ðà(ñø))
  • psychic energy
    Á¤½Å¿¡³ÊÁö.
  • radiant energy
    º¹»ç<¹æ»ç>¿¡³ÊÁö.(¹æ»ç¼±)¹æ»ç¿¡³ÊÁö.
  • radiant energy
    ¹æ»ç¿¡³ÊÁö
  • radiant energy absorption
    º¹»ç(¹æ»ç)¿¡³ÊÁöÈí¼ö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • islet-activation factor
    ¶û°Ô¸£Çѽº»ù Ȱ¼ºÀÎÀÚ, ¹éÀÏÇØ±Õµ¶¼Ò
  • macrophage,activation of
    Ȱ¼ºÈ­(üÀàõûù)
  • neutron activation analysis
    Áß¼ºÀÚ¹æ»çÈ­ºÐ¼®(~Û¯ÞÒûùÝÂà°).
  • photochemical activation
    ±¤È°¼ºÈ­(Ë´Ì· ËÛÌ´).
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
  • sleep activation
    ¼ö¸éºÎȰ(¹ý)(¡­Ý¥üÀÛö) ³úÆÄ(Òà÷î)ÀÇ .
  • thermal activation
    ¿­È°¼ºÈ­¹ÝÀÀ(æðüÀàõûù Úãëë).
  • tissue plasminogen activation
    Á¶Á÷ ÇöóÁî¹Ì°Õ Ȱ¼º
  • tissue plasminogen activation inhibitor
    Á¶Á÷ ÇöóÁî¹Ì³ë°Õ Ȱ¼º ¾ïÁ¦ÀÎÀÚ
  • trypsinogen activation peptide(TAP)
  • ventricular activation
    ½É½ÇÈïºÐ(ãýãøýéÝÇ).
  • ventricular activation
    ½É½ÇÈïºÐ(ãýãøýéÝÇ)
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£(ãýãøýéÝÇãÁÊà).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • neutron activation alalysis
    Áß¼ºÀÚ ¹æ»çÈ­ºÐ¼®(ñéàõí­Û¯ÞÒûùÝÂà°)
  • reciprocal activation
    »óº¸ Ȱ¼ºÈ­(ßÓÜÍüÀàõûù)
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
  • bond energy
    °áÇÕ(Ì¿ùê)¿¡³ÊÁö
  • energy
    ¿¡³ÊÁö
  • energy barrier
    ¿¡³ÊÁö À庮(î¡Ûú)
  • energy charge
    ¿¡³ÊÁö ÃæÁ·À²(õöðëëÒ)
  • energy coupling
    ¿¡³ÊÁö ¦Áþ±â
  • energy diagram
    ¿¡³ÊÁö µµÇ¥(Óñøú)
  • energy dispersive spectrometry
    ¿¡³ÊÁö ºÐ»êÃøÁ¤¹ý (ÝÂߤö´ïÒÛö)
  • energy-poor compound
    ºó(Þ¸)¿¡³ÊÁö È­ÇÕ¹°(ûùùêÚª)
  • energy-regenerating system
    ¿¡³ÊÁö Àç»ý(î¢ßæ) ½Ã½ºÅÛ
  • energy-rich bond
    ºÎ(Ý£)¿¡³ÊÁö °áÇÕ(Ì¿ùê)
  • energy-rich compound
    ºÎ(Ý£)¿¡³ÊÁö È­ÇÕ¹°(ûùùêÚª)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CMNA complement-mediated neutrophil activation
HIPA heparin-induced platelet activation
INAA instrumental neutron activation analysis
LAG labiogingival; leukocyte antigen group; linguo-axiogingival; lymphangiogram; lymphocyte activation g...
MA malignant arrhythmia; management and administration; mandelic acid; masseter; Master of Arts; matern...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ARI activation recovery interval
AT Activation time
FAP Fibroblast Activation Protein
HIPA Heparin-induced platelet activation
GAS IFN-gamma activation site
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dual energy
    ÀÌÁß ¿¡³ÊÁö
  • energetic exhibiting energy

    energetics

    ¿¡³ÊÁö·Ð, ¿¡³ÊÁöÇÐ
    ¿¡³ÊÁöÀÇ ¿¬±¸. ¿¡³ÊÁöÀÇ °úÇÐ.
  • energy
    ¿¡³ÊÁö
    1. ·¹ÀÌÀú¿¡ À־ ¿¡³ÊÁö´Â ½Ã°£°ú ÈûÀÌ °ö°ú °°´Ù. 2. ÀÏÀ» ÇÏ´Â ´É·Â, ¿îµ¿À» ÀÏÀ¸ÄѼ­ ÀúÇ×À» ±Øº¹ÇÏ¿© ¹°¸®Àû º¯È­¸¦ ÀÏÀ¸Å°´Â Èû.
  • energy charge
    ¿¡³ÊÁö ºÎÇÏ
  • energy dependency
    ¿¡³ÊÁö ÀÇÁ¸¼º
  • energy flux density
    ¿¡³ÊÁö¼Ó ¹Ðµµ
  • energy imparted
    ºÎ¿© ¿¡³ÊÁö
  • energy loss
    ¿¡³ÊÁö ¼Õ½Ç
  • energy metabolism
    ¿¡³ÊÁö ´ë»ç
  • energy parasite
    ¿¡³ÊÁö ±â»ýü
  • energy quotient
    ¿¡³ÊÁö À²
  • energy source
    ¿¡³ÊÁö ¿ø
  • high energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÎ»ê °áÇÕ ÇüŰ¡ ³ôÀº ¿¡³ÊÁö·Î ÀÌ·ç¾îÁø »óÅÂ. ÀÌ °áÇÕÀº ¾Æ³×³ë½Å »ïÀλê. Æ÷½ºÆ÷Å©·¹¾ÆÆ¾. ´ç ´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • high energy radiation
    °í¿¡³ÊÁö ¹æ»ç¼±
    ³ôÀº ¿¡³ÊÁöÀÇ ¹æ»ç¼±À» ¹æÃâÇÏ´Â °Í.
  • high-energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÌ °áÇÕÀº ¾Æµ¥³ë½Å »ïÀλê, Æ÷½ºÆ÷Å©·¹¾ÆÆ¾, ´ç´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
EEG activation The low voltage, fast pattern of attentive wakefulness.
(05 Mar 2000)
trans-activation (genetics) Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.)
(12 Dec 1998)
enzyme activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1) activation by ions (activators); 2) activation by cofactors (coenzymes); and 3) conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
(12 Dec 1998)
juxtacrine activation Activation of target cells by membrane anchored growth factors, also used for activation of leucocytes by PAF bound to endothelial cell surface.
(18 Nov 1997)
feedback activation The activation of an enzyme by an end product of a biochemical pathway in which that enzyme plays a part. For example, the activation of factors VIII and V by thrombin during blood clotting.
(05 Mar 2000)
feed-forward activation The activation of an enzyme by a precursor of the substrate of that enzyme.
(05 Mar 2000)
upstream activation site A DNA sequence that regulates transcription like an enhancer but does notwork if its located downstream from a promoter.
(09 Oct 1997)
low-activation materials <radiobiology> In fission reactors, one is forced to deal with the radioactive byproducts of the fission process, but in fusion reactors one generally has a choice of what materials to expose to neutrons produced by the fusion process. A major problem for fusion reactors is developing materials (such as for the reactor vacuum vessel structure) which can be exposed to high levels of neutron bombardment without becoming permanently radioactive. Candidate structural materials which have relatively low induced radiactivation (generally relative to stainless steel) are known as low-activation materials, these include titanium, vanadium, and silicon-carbide.
(09 Oct 1997)
lymphocyte activation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
binding energy <chemistry, radiobiology> The binding energy of a nucleus is the minimum energy required to dissociate it into its component neutrons and protons. Neutron or proton binding energies are those required to remove a neutron or proton, respectively, from a nucleus. Electron binding energy is that required to remove an electron from an atom or a molecule.
(16 Dec 1997)
bioelectric energy sources Implantable devices which convert biological energy (chemical energy of the metabolism of continuously regenerating body fluids or mechanical energy of periodic movements) to electrical energy. The sources include biogalvanic cells, biofuel cells, and ionic concentration cells.
(12 Dec 1998)
biomass energy See Bioenergy.
(05 Dec 1998)
bond dissociation energy This is the energy needed to break the bonds between two linked atoms.
(09 Oct 1997)
bond energy The energy needed to break a molecular bond.
(09 Oct 1997)
radiant energy Energy contained in light rays or any other form of radiation.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • energy crisis
    ¿¡³ÊÁö À§±â
  • energy flow
    (»ýŰèÀÇ)¿¡³ÊÁö È帧
  • energy industry
    ¿¡³ÊÁö »ê¾÷(¼®Åº,¼®À¯,Àü±â,°¡½º »ê¾÷ µî)
  • energy park
    (¹Ì)¿¡³ÊÁö ´ÜÁö;¿¡³ÊÁö ÀÚ¿ø °øµ¿ ÀÌ¿ëÁö
  • free energy
    ÀÚÀ¯ ¿¡³ÊÁö
  • kinetic energy
    ¿îµ¿ ¿¡³ÊÁö 
  • mass energy
    Áú·® ¿¡³ÊÁö
  • nuclear energy
    ÇÙ ¿¡³ÊÁö !
  • rest energy
    Á¤Áö¿¡³ÊÁö
  • solar energy
    ÅÂ¾ç ¿¡³ÊÁö !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á